文献速递泌尿生殖与妇科肿瘤放疗

Vienna-II环形施源器用于宫颈癌近距离治疗中远端宫旁/盆壁病变:两机构临床可行性与结局

Vienna-II ring applicator for distal parametrial/pelvic wall disease in cervical cancer brachytherapy: An experience from two institutions: Clinical feasibility and outcome.
PubMed 文献 · Radiother Oncol · 2019-09-05

本研究纳入69例同步放化疗后远端宫旁/盆壁残留的局部晚期宫颈癌患者,采用Vienna-II环形施源器行图像引导自适应近距离治疗。结果显示该施源器可行,靶区覆盖充分,3/5年局部控制率为76/72%,总生存率为62/54%,≥G3晚期毒性见于20%患者。

要点

  • Vienna-II施源器在远端宫旁/盆壁残留宫颈癌中临床可行,靶区覆盖满意。
  • 3/5年局部控制率76/72%,无进展生存率56/50%,总生存率62/54%。
  • ≥G3晚期毒性见于14例(20%),急性并发症可控。

核心结论

  • 使用Vienna-II施源器行图像引导自适应近距离治疗,可为近距离治疗时肿瘤延伸至远端宫旁/盆壁者提供适当靶区覆盖,临床可行且局部控制、无病生存和总生存良好,≥G3急性和晚期毒性发生率中等。

研究设计与样本

  • 两机构回顾性研究,纳入69例同步放化疗后远端宫旁/盆壁残留的局部晚期宫颈癌患者,均使用Vienna-II施源器行图像引导自适应近距离治疗。

主要发现

  • 近距离治疗时90%患者存在远端宫旁/盆壁残留病变。
  • 中位总插植针数7根[3-15],斜插针中位4根[1-7]。
  • 8例发生可处理的术中子宫阴道并发症,6例取针时发生可处理的动脉出血。
  • 宫腔管与CTVHR外轮廓平均距离38 mm,CTVHR平均体积69±32 cm³。
  • CTVHR平均D90为86±7 Gy(EQD2),膀胱、直肠、乙状结肠平均D2cm³分别为86±12、68±7、68±9 Gy(EQD2)。

关键数值与推荐

  • FIGO(2009)分期:IIB期26%、III期52%、IVA期15%、IVB期(腹主动脉旁淋巴结)7%。
  • 诊断时91%患者病变累及远端宫旁/盆壁。

临床怎么用

  • 对同步放化疗后远端宫旁/盆壁残留的局部晚期宫颈癌,可考虑使用Vienna-II施源器行图像引导自适应近距离治疗以提高靶区覆盖。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Recent evidence from EMBRACE shows that around 16% patients with locally advanced cervical cancer (LACC) have residual tumor in distal parametrium (DP) and pelvic wall disease (LPW) after concurrent radio-chemotherapy (CCRT). Adequate target coverage with standard brachytherapy approaches represents a challenge. Therefore, we modified the Vienna I applicator with an add-on cap allowing for additional oblique needles into the DP/LPW (Vienna II). We report here the feasibility and clinical outcomes using Vienna II applicator in LACC patients treated in 2 institutions. METHODS AND MATERIALS: 69 patients with residual disease in DP/LPW after CCRT were accrued. FIGO (2009) stage was 26% IIB, 52% III, 15% IVA, 7% IVB (para-aortic nodes). At diagnosis 91% had disease involving DP/LPW. After CCRT, patients underwent image guided adaptive brachytherapy (IGABT) using Vienna II applicator. IGABT details, acute complications, dose volume parameters and clinical outcome variables were compiled and analyzed. RESULTS: Residual DP/LPW disease at BT was found in 90% patients. Median total number of needles were 7 [3-15], oblique 4 [1-7]. Manageable intraoperative utero-vaginal complications occurred in 8 patients and manageable arterial bleeding in 6 patients during removal. Mean distance between tandem and outer contour of CTVHR was 38 mm and mean CTVHR (±SD) volume was 69 ± 32 cm3. The mean D90 CTVHR was 86 ± 7 Gy (EQD2) and mean (±SD) D2cm3 (Gy, EQD2) 86 ± 12, 68 ± 7, 68 ± 9 for bladder, rectum and sigmoid respectively. Actuarial LC, PFS, OS at 3/5 years was 76/72%, 56/50%, 62/54% and G3-4 late toxicities (n = 23) were observed in 14 patients (20%). CONCLUSIONS: IGABT using Vienna II applicator allows for appropriate target coverage in tumors extending into DP/LPW at the time of BT. Clinical use is feasible and results in good local control, DFS and OS with moderate rate of acute and late ≥G3 toxicity.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Mahantshetty U, Sturdza A, Naga Ch P, et al. Vienna-II ring applicator for distal parametrial/pelvic wall disease in cervical cancer brachytherapy: An experience from two institutions: Clinical feasibility and outcome. Radiother Oncol. 2019. PMID: 31495516. doi:10.1016/j.radonc.2019.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。